Vincent L. Giranda
- Molecular Biology top 2%
- Oncology top 1%
- Organic Chemistry top 5%
- Cancer Research top 5%
- Pulmonary and Respiratory Medicine top 5%
- Co-authors
- Yan LuoXuesong LiuYan ShiEric F. JohnsonJennifer J. BouskaV. NienaberKeith W. WoodsThomas D. Penning
- Topics
- PARP inhibition in cancer therapy (59 papers)DNA Repair Mechanisms (27 papers)PI3K/AKT/mTOR signaling in cancer (15 papers)
- Journals
- Proceedings of the National Academy of SciencesJournal of Biological ChemistryJournal of Clinical Oncology
- Partner nations
- United StatesUnited KingdomCanada
In The Last Decade
Vincent L. Giranda
114 papers receiving 4.2k citations
Peers
Comparison fields: 5 of 119
- Molecular Biology 2.5k
- Oncology 2.1k
- Organic Chemistry 598
- Cancer Research 552
- Pulmonary and Respiratory Medicine 402
Countries citing papers authored by Vincent L. Giranda
This map shows the geographic impact of Vincent L. Giranda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincent L. Giranda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincent L. Giranda more than expected).
Fields of papers citing papers by Vincent L. Giranda
This network shows the impact of papers produced by Vincent L. Giranda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincent L. Giranda. The network helps show where Vincent L. Giranda may publish in the future.
Co-authorship network of co-authors of Vincent L. Giranda
This figure shows the co-authorship network connecting the top 25 collaborators of Vincent L. Giranda. A scholar is included among the top collaborators of Vincent L. Giranda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vincent L. Giranda. Vincent L. Giranda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 33 | |
| 3 | 16 | |
| 4 | 65 | |
| 5 | 69 | |
| 6 | 75 | |
| 7 | 69 | |
| 8 | 11 | |
| 9 | 111 | |
| 10 | 77 | |
| 11 | Abstract #3602: Ongoing phase 1 study of a novel PARP inhibitor, ABT-888 in combination with temozolamide; Pharmacokinetics, safety and anti-tumor activity | 2 |
| 12 | 21 | |
| 13 | 58 | |
| 14 | 42 | |
| 15 | 31 | |
| 16 | 122 | |
| 17 | 24 | |
| 18 | Abrogation of G2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents. | 28 |
| 19 | 40 | |
| 20 | 5 |
About Vincent L. Giranda
Vincent L. Giranda is a scholar working on Oncology, Cancer Research and Genetics, having authored 115 papers that have together received 4.4k indexed citations. Recurring topics across this work include PARP inhibition in cancer therapy (59 papers), DNA Repair Mechanisms (27 papers) and PI3K/AKT/mTOR signaling in cancer (15 papers). The work is most often cited by research in Oncology (2.1k citations), Molecular Biology (2.5k citations) and Cancer Research (552 citations). Vincent L. Giranda has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Yan Luo, Xuesong Liu, Yan Shi, Eric F. Johnson, Jennifer J. Bouska, V. Nienaber, Keith W. Woods, Thomas D. Penning, Vered Klinghofer and Kent D. Stewart. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.